Bortezomib + Rituximab + Rituximab
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Hodgkin's Lymphoma
Conditions
Non-Hodgkin's Lymphoma
Trial Timeline
Mar 1, 2006 โ Jul 1, 2010
NCT ID
NCT00312845About Bortezomib + Rituximab + Rituximab
Bortezomib + Rituximab + Rituximab is a phase 3 stage product being developed by Johnson & Johnson for Non-Hodgkin's Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00312845. Target conditions include Non-Hodgkin's Lymphoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00312845 | Phase 3 | Completed |
Competing Products
20 competing products in Non-Hodgkin's Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YM155 + Rituximab | Astellas Pharma | Phase 2 | 52 |
| Tazemetostat | Eisai | Phase 2 | 52 |
| ONTAK | Eisai | Phase 2 | 52 |
| Tazemetostat | Eisai | Phase 1 | 33 |
| ME-401 | Kyowa Kirin | Phase 1 | 33 |
| ME-401 | Kyowa Kirin | Phase 2 | 52 |
| gemcitabine | Eli Lilly | Phase 2 | 52 |
| gemcitabine + cisplatin + dexamethasone | Eli Lilly | Phase 2 | 52 |
| LY317615 | Eli Lilly | Phase 2 | 52 |
| LY4584180 + Rituximab | Eli Lilly | Phase 1 | 33 |
| HRS-3738 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| SHR1459 ๏ผYY-20394 + SHR1459 ๏ผYY-20394 + Gemcitabine-Oxaliplatin | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| ABT-199 + Ketoconazole | AbbVie | Phase 1 | 33 |
| ABT-199 + Rifampin | AbbVie | Phase 1 | 33 |
| [14C]ABT-199 (GDC-0199) | AbbVie | Phase 1 | 33 |
| ABT-199 + Rituximab + Bendamustine | AbbVie | Phase 1 | 33 |
| ABBV-291 | AbbVie | Phase 1 | 33 |
| ABT-199 | AbbVie | Phase 1 | 33 |
| Avelumab | Merck | Phase 1 | 33 |
| Pembrolizumab + Flt3L + Poly ICLC | Merck | Phase 1/2 | 41 |